Italia markets close in 4 hours 3 minutes

Oxurion NV (0G99.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
0,0001-0,0003 (-75,00%)
In data: 03:29PM GMT. Mercato aperto.
Schermo intero
Chiusura precedente0,0004
Aperto0,0000
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume0
Media Volume8.955
Capitalizzazione38
Beta (5 anni mensile)0,51
Rapporto PE (ttm)N/D
EPS (ttm)-0,7590
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

    Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion. Leuven, BELGIUM, Boston, MA, US – October 10, 2023 – 08.00 PM CET – In accordance w

  • GlobeNewswire

    Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

    Regulated Information Leuven, BELGIUM, Boston, MA, US – October 3, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on October 3, 2023, from Atlas Special Opportunities, L

  • GlobeNewswire

    Oxurion Publishes First Half 2023 Results

    Regulated Information Leuven, BELGIUM, Boston, MA, US – September 29, 2023 – 7.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2023. The half-year report is available in the “Investors” section of the Company’s website and can also be downloaded as a PDF.